Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Air Products' (APD) Stock Rises 16% In 6 Months: Here's Why

Published 11/28/2019, 06:14 AM
Updated 07/09/2023, 06:31 AM

Shares of Air Products and Chemicals, Inc. (NYSE:APD) have popped 16.3% over the past six months. The company has also outperformed its industry’s growth of roughly 1.5% over the same time frame.

Air Products, a Zacks Rank #3 (Hold) stock, has a market cap of roughly $52 billion and average volume of shares traded in the last three months was around 954.2K. The company has an expected long-term earnings per share growth rate of 12.3%, above the industry average of 10%.


Let’s take a look into the factors that are driving this industrial gases giant.

What’s Favoring the Stock?

Upbeat outlook for fiscal 2020 and healthy growth prospects have contributed to the run-up in Air Products’ shares.

Air Products, in its fiscal fourth-quarter call, said that it expects adjusted earnings for fiscal 2020 in the range of $9.35-$9.60 per share. This calls for a 14-17% rise year over year. The company expects adjusted EPS for first-quarter fiscal 2020 in the band of $2.05-$2.10, which indicates 10-13% rise year over year.

The Zacks Consensus Estimate for earnings for fiscal 2020 of $9.48 reflects an expected year-over-year growth of 15.5%. Moreover, earnings are expected to register a 11.8% growth in the fiscal first quarter.

Earnings estimates for fiscal 2020 are also going up over the past month. Over this period, the Zacks Consensus Estimate for the fiscal has moved up 1.4%.

Air Products’ strategic investments in high-return projects, new project wins, productivity actions and contributions of acquisitions should drive its fiscal 2020 results. Notably, the Lu'An syngas project in China is contributing to the results in the company’s Industrial Gases – Asia segment. In the last reported quarter, the company’s volumes this segment jumped roughly 16% on the back of new projects, including the Lu'An project.

The company also expects the Jazan gas and power project in Saudi Arabia to contribute to the growth in its adjusted per share in fiscal 2020.

The company has a total available capacity to deploy (over fiscal 2018-2022) nearly $18 billion in high-return investments, aimed at creating significant shareholder value. It has already spent or committed more than half of this capacity.

Air Products also remains committed to boost productivity to improve its cost structure. The company is seeing positive impact of its productivity actions and is expected to benefit from additional productivity and cost improvement programs in fiscal 2020.

Moreover, Air Products remains committed to maximize returns to shareholders. the company generated roughly $2.7 billion of distributable cash flow during fiscal 2019. This marks an increase of nearly 20% from fiscal 2018 levels. This distributable cash flow enabled it to pay roughly $1 billion or around 40% as dividends to shareholders.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Stocks to Consider

Some better-ranked stocks worth considering in the basic materials space include Kirkland Lake Gold Ltd. (TSX:KL) , Agnico Eagle Mines Limited (NYSE:AEM) and Franco-Nevada Corporation (TSX:FNV) .

Kirkland Lake Gold has projected earnings growth rate of 96.3% for the current year and sports a Zacks Rank #1 (Strong Buy). The company’s shares have surged around 95% in a year’s time. You can see the complete list of today’s Zacks #1 Rank stocks here.

Agnico Eagle has a projected earnings growth rate of 168.6% for the current year and carries a Zacks Rank #2 (Buy). The company’s shares have rallied roughly 67% in a year’s time.

Franco-Nevada has estimated earnings growth rate of 46.2% for the current year and carries a Zacks Rank #2. The company’s shares have shot up roughly 43% in a year’s time.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Air Products and Chemicals, Inc. (APD): Free Stock Analysis Report

Agnico Eagle Mines Limited (AEM): Free Stock Analysis Report

Franco-Nevada Corporation (FNV): Free Stock Analysis Report

Kirkland Lake Gold Ltd. (KL): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.